Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

UK Active Pharmaceutical Ingredient Cancer Market

ID: MRFR/Pharma/49240-HCR
200 Pages
Nidhi Mandole
Last Updated: March 28, 2026

UK Active Pharmaceutical Ingredient for Cancer Market Research Report By Type (Small Molecules, Biologics, Monoclonal Antibodies, Vaccines), By Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer), By Manufacturing Process (Chemical Synthesis, Biotechnology, Extraction), and By Formulation (Tablets, Injectables, Oral Solutions, Topical) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

UK Active Pharmaceutical Ingredient Cancer Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Application (USD Billion)
  49.     4.1.1 Chemotherapy
  50.     4.1.2 Targeted Therapy
  51.     4.1.3 Immunotherapy
  52.     4.1.4 Hormonal Therapy
  53.   4.2 Healthcare, BY Drug Type (USD Billion)
  54.     4.2.1 Cytotoxic Drugs
  55.     4.2.2 Hormonal Agents
  56.     4.2.3 Biologics
  57.     4.2.4 Targeted Agents
  58.   4.3 Healthcare, BY Formulation Type (USD Billion)
  59.     4.3.1 Injectable
  60.     4.3.2 Oral
  61.     4.3.3 Topical
  62.     4.3.4 Intravenous
  63.   4.4 Healthcare, BY Route of Administration (USD Billion)
  64.     4.4.1 Intravenous
  65.     4.4.2 Oral
  66.     4.4.3 Subcutaneous
  67.     4.4.4 Intramuscular
  68.   4.5 Healthcare, BY Patient Demographics (USD Billion)
  69.     4.5.1 Pediatric
  70.     4.5.2 Adult
  71.     4.5.3 Geriatric
  72. 5 SECTION V: COMPETITIVE ANALYSIS
  73.   5.1 Competitive Landscape
  74.     5.1.1 Overview
  75.     5.1.2 Competitive Analysis
  76.     5.1.3 Market share Analysis
  77.     5.1.4 Major Growth Strategy in the Healthcare
  78.     5.1.5 Competitive Benchmarking
  79.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  80.     5.1.7 Key developments and growth strategies
  81.       5.1.7.1 New Product Launch/Service Deployment
  82.       5.1.7.2 Merger & Acquisitions
  83.       5.1.7.3 Joint Ventures
  84.     5.1.8 Major Players Financial Matrix
  85.       5.1.8.1 Sales and Operating Income
  86.       5.1.8.2 Major Players R&D Expenditure. 2023
  87.   5.2 Company Profiles
  88.     5.2.1 AstraZeneca (GB)
  89.       5.2.1.1 Financial Overview
  90.       5.2.1.2 Products Offered
  91.       5.2.1.3 Key Developments
  92.       5.2.1.4 SWOT Analysis
  93.       5.2.1.5 Key Strategies
  94.     5.2.2 GlaxoSmithKline (GB)
  95.       5.2.2.1 Financial Overview
  96.       5.2.2.2 Products Offered
  97.       5.2.2.3 Key Developments
  98.       5.2.2.4 SWOT Analysis
  99.       5.2.2.5 Key Strategies
  100.     5.2.3 Bristol-Myers Squibb (US)
  101.       5.2.3.1 Financial Overview
  102.       5.2.3.2 Products Offered
  103.       5.2.3.3 Key Developments
  104.       5.2.3.4 SWOT Analysis
  105.       5.2.3.5 Key Strategies
  106.     5.2.4 Novartis (CH)
  107.       5.2.4.1 Financial Overview
  108.       5.2.4.2 Products Offered
  109.       5.2.4.3 Key Developments
  110.       5.2.4.4 SWOT Analysis
  111.       5.2.4.5 Key Strategies
  112.     5.2.5 Roche (CH)
  113.       5.2.5.1 Financial Overview
  114.       5.2.5.2 Products Offered
  115.       5.2.5.3 Key Developments
  116.       5.2.5.4 SWOT Analysis
  117.       5.2.5.5 Key Strategies
  118.     5.2.6 Pfizer (US)
  119.       5.2.6.1 Financial Overview
  120.       5.2.6.2 Products Offered
  121.       5.2.6.3 Key Developments
  122.       5.2.6.4 SWOT Analysis
  123.       5.2.6.5 Key Strategies
  124.     5.2.7 Merck & Co. (US)
  125.       5.2.7.1 Financial Overview
  126.       5.2.7.2 Products Offered
  127.       5.2.7.3 Key Developments
  128.       5.2.7.4 SWOT Analysis
  129.       5.2.7.5 Key Strategies
  130.     5.2.8 Sanofi (FR)
  131.       5.2.8.1 Financial Overview
  132.       5.2.8.2 Products Offered
  133.       5.2.8.3 Key Developments
  134.       5.2.8.4 SWOT Analysis
  135.       5.2.8.5 Key Strategies
  136.     5.2.9 Teva Pharmaceutical Industries (IL)
  137.       5.2.9.1 Financial Overview
  138.       5.2.9.2 Products Offered
  139.       5.2.9.3 Key Developments
  140.       5.2.9.4 SWOT Analysis
  141.       5.2.9.5 Key Strategies
  142.   5.3 Appendix
  143.     5.3.1 References
  144.     5.3.2 Related Reports
  145. 6 LIST OF FIGURES
  146.   6.1 MARKET SYNOPSIS
  147.   6.2 UK MARKET ANALYSIS BY APPLICATION
  148.   6.3 UK MARKET ANALYSIS BY DRUG TYPE
  149.   6.4 UK MARKET ANALYSIS BY FORMULATION TYPE
  150.   6.5 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  151.   6.6 UK MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
  152.   6.7 KEY BUYING CRITERIA OF HEALTHCARE
  153.   6.8 RESEARCH PROCESS OF MRFR
  154.   6.9 DRO ANALYSIS OF HEALTHCARE
  155.   6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  156.   6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  157.   6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
  158.   6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
  159.   6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
  160.   6.15 HEALTHCARE, BY DRUG TYPE, 2024 (% SHARE)
  161.   6.16 HEALTHCARE, BY DRUG TYPE, 2024 TO 2035 (USD Billion)
  162.   6.17 HEALTHCARE, BY FORMULATION TYPE, 2024 (% SHARE)
  163.   6.18 HEALTHCARE, BY FORMULATION TYPE, 2024 TO 2035 (USD Billion)
  164.   6.19 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
  165.   6.20 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
  166.   6.21 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
  167.   6.22 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Billion)
  168.   6.23 BENCHMARKING OF MAJOR COMPETITORS
  169. 7 LIST OF TABLES
  170.   7.1 LIST OF ASSUMPTIONS
  171.     7.1.1
  172.   7.2 UK MARKET SIZE ESTIMATES; FORECAST
  173.     7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
  174.     7.2.2 BY DRUG TYPE, 2026-2035 (USD Billion)
  175.     7.2.3 BY FORMULATION TYPE, 2026-2035 (USD Billion)
  176.     7.2.4 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Billion)
  177.     7.2.5 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Billion)
  178.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  179.     7.3.1
  180.   7.4 ACQUISITION/PARTNERSHIP
  181.     7.4.1

UK Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2026-2035)

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Hormonal Therapy

Healthcare By Drug Type (USD Billion, 2026-2035)

  • Cytotoxic Drugs
  • Hormonal Agents
  • Biologics
  • Targeted Agents

Healthcare By Formulation Type (USD Billion, 2026-2035)

  • Injectable
  • Oral
  • Topical
  • Intravenous

Healthcare By Route of Administration (USD Billion, 2026-2035)

  • Intravenous
  • Oral
  • Subcutaneous
  • Intramuscular

Healthcare By Patient Demographics (USD Billion, 2026-2035)

  • Pediatric
  • Adult
  • Geriatric

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓